Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis;Postprandiale hyperglykämie als risikofaktor bei herz-kreislauf- erkrankungen. Therapie verbessert prognose

Herz

Volumn 29, Issue 5, 2004, Pages 480-487

  Hanefeld, Markolf ^a   Schaper, Frank ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Cardiovascular disease; Intervention studies; Postprandial hyperglycemia; Prediabetes; Risk factor

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STATIN;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; COMMON CAROTID ARTERY; CRITICAL ILLNESS; DIABETES CONTROL; DIET RESTRICTION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; LIFE EXPECTANCY; OXIDATIVE STRESS; POSTPRANDIAL STATE; PROGNOSIS; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; COMORBIDITY; HUMANS; HYPERGLYCEMIA; INCIDENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 4444336802     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-004-2608-y     Document Type: Review

References (65)

1. Panzram G, Zabel-Langhennig R. Prognosis of diabetes mellitus in a geographically defined population. Diabetologia 1981;20:587-91.
2. Pyorala K. Hyperinsulinaemia as predictor of atherosclerotic vascular disease: epidemiological evidence. Diabete Metab 1991;17:87-92.
3. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-7.
4. Turner RC, Millns H, Neil HAW, et al., for the United Kingdom Prospective Diabetes Study Croup. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998;316:823-8.
5. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83.
6. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996;347:949-50.
7. Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabet Med 1997;14:Suppl 3:56-11.
8. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
9. Hanefeld M. Postprandialer Status und Prognose des Diabetes: Konsequenzen für die Therapie. Diabetes Stoffw 1999;8:Suppl 6:3-8.
10. American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001;24:775-8.
11. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-96.
12. Hu G, DECODE Study Croup. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly diagnosed diabetes. Diabetologia 2003;46:608-17.
13. Curb JD, Rodriguez BL, Burchfiel CM, et al. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation 1995;91:2591-5.
14. Burchfiel CM, Curb JD, Rodriguez BL, et al. Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke 1994;25:951-7.
15. Ross GW, Petrovitch H, White LR, et al. Characterization of risk factors for vascular dementia: the Honolulu-Asia Aging Study. Neurology 1999;53:337-43.
16. De Vegt F, Dekker JM, Ruhe HC, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-31.
17. Gerritsen J, Dekker JM, TenVoorde BJ, et al. Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study. Diabetologia 2000;43:561-70.
18. Schram MT, Henry RM, van Dijk RA, et al. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension 2004;43:176-81.
19. Henry RM, Kamp O, Kostense PJ, et al. Left ventricular mass increases with deteriorating glucose tolerance, especially in women: independence of increased arterial stiffness or decreased flow-mediated dilation: the Hoorn Study. Diabetes Care 2004;27:522-9.
20. Beks PH, Mackaay AJ, de Vries H, et al. Carotid artery stenosis is related to blood glucose level in an elderly Caucasian population: the Hoorn Study. Diabetologia 1997;40:290-8.
21. Hanefeld M, Koehler C, Schaper F, et al. Postprandial plasma glucose is an independent risk factor for increased intima-media thickness in non-diabetic individuals. Atherosclerosis 1999;144:229-35.
22. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360-7.
23. Eschwege E, Balkau B. Hyperglycaemia: link to excess mortality. Int J Clin Pract Suppl 2001;123:3-6.
24. Fuller JH, Shipley MJ, Rose G, et al. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall Study. Br Med J [Clin Res] 1983;287:867-70.
25. Balkau B, Forhan A, Eschwege E. Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris Prospective Study. Diabetologia 2002;45:1224-30.
26. Eschwege A, Charles MA, Simon D, et al. From policemen to policies: what is the future for 2-h glucose? The Kelly West Lecture, 2000. Diabetes Care 2001;24:1945-50.
27. Meigs JB, Nathan DM, D'Agostino RB Sr, et al. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25:1845-50.
28. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998;21:1236-9.
29. Sasso FC, Carbonara O, Nasti R, et al. Glucose metabolism and coronary heart disease in patients with normal glucose tolerance. JAMA 2004;291:1857-63.
30. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920-4.
31. Saitoh T, Daimon M, Eguchi H, et al. Type 2 diabetes is not a risk factor for asymptomatic ischemic brain lesion - the Funagata Study. Intern Med 2002;41:351-6.
32. Malmberg K, Ryden L, Hamsten A, et al. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI Study [Erratum in: Cardiovasc Res 1997;36:460]. Cardiovasc Res 1997;34:248-53.
33. Malmberg K, Ryden L, Hamsten A, et al. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI Study [Erratum in: Cardiovasc Res 1997;36:460]. Cardiovasc Res 1997;34:248-53.
34. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314:1512-5.
35. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
36. Nakamura N, Ueno Y, Tsuchiyama Y, et al. Isolated post-challenge hyperglycemia in patients with normal fasting glucose concentration exaggerates neointimal hyperplasia after coronary stent implantation. Circ J 2003;67:61-7.
37. Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl 2002;129:5-11.
38. Qiao Q, Pyorala K, Pyorala M, et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002;23:1229-31.
39. Betteridge DJ. Lipids and atherogenesis in diabetes mellitus. Atherosclerosis 1996;124:Suppl:S43-7.
40. Bos G, Dekker JM, Nijpels G, et al. A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism - the Hoorn Study. Diabetologia 2003;46:910-6.
41. Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002;45:461-75.
42. Ceriello A. Nitrotyrosine: new findings as a marker of postprandial oxidative stress. Int J Clin Pract Suppl 2002;129:51-8.
43. Ceriello A, Lizzio S, Bortolotti N, et al. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care 1998;21:1529-33.
44. Vogl-Willis CA, Edwards IJ. High glucose-induced alterations in subendothelial matrix perlecan leads to increased monocyte binding. Arterioscler Thromb Vasc Biol 2004, Mar 18 [pub ahead of print].
45. Krogh-Madsen R, Moller K, Dela F, et al. Hyperglycemia induced by glucose infusion causes hepatic oxidative stress and systemic inflammation, but not STAT3 or MAP kinase activation in liver in rats. Metabolism 2003;52:868-74.
46. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-54.
47. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-72.
48. Ceriello A, Quagliaro L, D'Amico M, et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 2002;51:1076-82.
49. Tomiyama H, Kushiro T, Okazaki R, et al. Influences of increased oxidative stress on endothelial function, platelets function, and fibrinolysis in hypertension associated with glucose intolerance. Hypertens Res 2003;4:295-300.
50. Puls W, Krause HP, Muller L, et al. Inhibitors of the rate of carbohydrate and lipid absorption by the intestine. Int J Obes 1984;8:Suppl 1:181-90.
51. Ceriello A, Taboga C, Tonutti L, et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996;39:469-73.
52. Schiekofer S, Andrassy M, Chen J, et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, P42/44 MAPK, and nuclear factor kappaB in PBMCs [Erratum in: Diabetes 2003;52:1307]. Diabetes 2003;52:621-33.
53. Schiekofer S, Andrassy M, Chen J, et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, P42/44 MAPK, and nuclear factor kappaB in PBMCs [Erratum in: Diabetes 2003;52:1307]. Diabetes 2003;52:621-33.
54. Rudofsky G, Reismann P, Schiekofer S, et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-κB activation in PBMCs. Horm Metab Res 2004:in press.
55. Sampson MJ, Davies IR, Brown JC, et al. Monocyte and neutrophil adhesion molecule expression during acute hyperglycemia and after antioxidant treatment in type 2 diabetes and control patients. Arterioscler Thromb Vasc Biol 2002;22:1187-93.
56. Shanmugam N, Reddy MA, Guha M, et al. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003;52:1256-64.
57. Temelkova-Kurktschiev T, Henkel E, Koehler C, et al. Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 2002;45:151.
58. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 1995;44:369-74.
59. Hales CN, Barker DJ. The thrifty phenotype hypothesis. Br Med Bull 2001;60:5-20.
60. Barker DJ. Coronary heart disease: a disorder of growth. Horm Res 2003;59: Suppl 1:35-41.
61. Reaven GM. Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia. Diabetes Obes Metab 2002;Suppl 1:13-8.
62. De Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995;333:1237-41.
63. Chiasson JL, Josse RG, Gomis R, et al., STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 2003;290:486-94.
64. Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004;35:1073-8.
65. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-6.